Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.35 | N/A | +5.86% |
management commentary, guidance changes, and full analysis available with Pro.
| +5.86% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, they did not provide specific guidance for the upcoming quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
This earnings report indicates that Johnson & Johnson was able to exceed EPS expectations, which is a positive sign for the company's profitability. However, the lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is not available, making it difficult to assess immediate market sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
F N B CORP PA
Jan 23, 2023